Form 4: Rhythm Pharmaceuticals CFO Hunter C. Smith Reports Stock Transactions

Hunter C. Smith, CFO of Rhythm Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units to cover withholding taxes.

Summary

• On February 9, 2025, Hunter C. Smith, CFO of Rhythm Pharmaceuticals, acquired 4,062 shares of common stock through the vesting of restricted stock units.
• On February 11, 2025, Smith acquired 2,343 shares of common stock through vesting of restricted stock units.
• Also on February 11, 2025, Smith disposed of 1,291 shares at $57.51 and 5 shares at $57.53 to cover withholding taxes related to the vesting of restricted stock units.
• Following these transactions, Smith directly owns 106,295 shares of Rhythm Pharmaceuticals common stock.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation and tax obligations.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates

Keywords

Rhythm Pharmaceuticals, Hunter C. Smith, RYTM, Form 4, Stock Transactions, Restricted Stock Units, CFO, Beneficial Ownership